Innocan Pharma Corp
F:IP4
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innocan Pharma Corp
F:IP4
|
IL |
|
O
|
Oriental Rise Holdings Ltd
NASDAQ:ORIS
|
CN |
|
M
|
McDonald's Corp
SWB:MDO
|
US |
|
S
|
Sogefi SpA
MIL:SO
|
IT |
|
M
|
Mckesson Corp
SWB:MCK
|
US |
|
B
|
Bper Banca SpA
F:4BE
|
IT |
|
Davide Campari Milano NV
OTC:DVDCF
|
IT |
|
Mesoblast Ltd
ASX:MSB
|
AU |
|
Stellantis NV
PAR:STLAP
|
NL |
|
SEPC Ltd
NSE:SEPC
|
IN |
|
Evgen Pharma PLC
LSE:EVG
|
UK |
|
T
|
thyssenkrupp AG
LSE:0O1C
|
DE |
|
K
|
KLA Corp
XBER:KLA
|
US |
|
Selamat Sempurna Tbk PT
IDX:SMSM
|
ID |
|
Tech Mahindra Ltd
NSE:TECHM
|
IN |
|
Flutter Entertainment PLC
LSE:FLTR
|
IE |
|
F
|
Fujikura Ltd
XBER:FJK
|
JP |
|
S
|
Sanlam Ltd
JSE:SLM
|
ZA |
|
A
|
American Water Works Company Inc
XBER:AWC
|
US |
|
R
|
Royal Bank of Canada
XBER:RYC
|
CA |
|
KeyCorp
NYSE:KEY
|
US |
|
D
|
Devon Energy Corp
BMV:DVN
|
US |
|
C
|
Casio Computer Co Ltd
DUS:CAC1
|
JP |
|
Purple Innovation Inc
NASDAQ:PRPL
|
US |
Innocan Pharma Corp
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items. Its main customers are the healthcare and pharmaceutical markets, including patients, doctors, and eventually distributors or partners that can commercialize approved products. Innocan makes money through product development, licensing, and collaboration with third parties, with its value tied to moving cannabinoid science through testing, regulatory review, and into sellable medicines. What makes the business different is that it sits between the cannabis industry and drug development. Instead of selling flowers, oils, or wellness products directly to consumers, Innocan is working on injectable and topical formulations that could become prescription-grade treatments, which puts it in a more research-driven and regulated part of the market.
Innocan Pharma Corp develops drug products based on cannabinoids, the active compounds from cannabis plants, with a focus on long-acting therapies for pain relief and other medical uses. The company is trying to turn cannabis-derived ingredients into regulated pharmaceutical products rather than consumer hemp or recreational items.
Its main customers are the healthcare and pharmaceutical markets, including patients, doctors, and eventually distributors or partners that can commercialize approved products. Innocan makes money through product development, licensing, and collaboration with third parties, with its value tied to moving cannabinoid science through testing, regulatory review, and into sellable medicines.
What makes the business different is that it sits between the cannabis industry and drug development. Instead of selling flowers, oils, or wellness products directly to consumers, Innocan is working on injectable and topical formulations that could become prescription-grade treatments, which puts it in a more research-driven and regulated part of the market.
